Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

sFOLFOXIRI i avansert gastroøsofageal kreft, (SAGE)

21. september 2026 oppdatert av: Patrick M Boland, MD, Rutgers, The State University of New Jersey

En fase II-studie av sFOLFOXIRI i avansert gastroøsofageal kreft (SAGE)

The primary objective is to determine the clinical efficacy of treatment regimen in terms of objective response rate (ORR). The secondary objectives is to determine the clinical efficacy of the study treatment in terms of progression free survival (PFS) and overall survival (OS). Additionally, to characterize the safety and toxicity profile of the study treatment as measured by the adverse event rates.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

The overall purpose of this protocol is to serve as a Single Arm Phase II trial of a four week alternating FOLFOX and FOLFIRI (sFOLFOXIRI), with or without nivolumab, in advanced human epidermal growth factor receptor two (HER2) negative gastric and esophageal cancers (GEC). This study evaluates the hypothesis that the use of sFOLFOXIRI in gastroesophageal cancer (GEC) will increase response rates beyond that expected with FOLFOX, while maintaining acceptable tolerability. The primary endpoint of this study is the objective response rate (ORR) while the key secondary endpoints include the progression free survival (PFS), overall survival (OS), and adverse event (AE) rates. The goal of this study is to establish the activity level of sFOLFOXIRI, with the thought that this could be further developed in the metastatic and/or peri-operative space if a sufficiently interesting degree of efficacy is observed.

Studietype

Intervensjonell

Registrering (Antatt)

38

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • New Jersey
      • Hamilton, New Jersey, Forente stater, 08690
        • Rekruttering
        • RWJBarnabas Health - Robert Wood Johnson University Hospital
        • Ta kontakt med:
          • Patrick Boland, MD
      • Lakewood, New Jersey, Forente stater, 08701
        • Rekruttering
        • RWJBarnabas Health - Monmouth Medical Center Southern Campus
        • Ta kontakt med:
          • Patrick Boland, MD
      • Long Branch, New Jersey, Forente stater, 07740
        • Rekruttering
        • RWJBarnabas Health - Monmouth Medical Center
        • Ta kontakt med:
          • Patrick Boland, MD
      • New Brunswick, New Jersey, Forente stater, 08903
        • Rekruttering
        • Rutgers Cancer Institute of New Jersey
        • Ta kontakt med:
          • Patrick Boland, MD
      • New Brunswick, New Jersey, Forente stater, 08903
        • Rekruttering
        • RWJBarnabas Health - Robert Wood Johnson University Hospital, Somerset
        • Ta kontakt med:
          • Patrick Boland, MD
      • Newark, New Jersey, Forente stater, 07112
        • Rekruttering
        • RWJBarnabas Health - Newark Beth Israel Medical Center
        • Ta kontakt med:
          • Patrick Boland, MD

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Histologically and/or cytologically confirmed metastatic or unresectable adenocarcinoma of esophageal, gastroesophageal junction or gastric origin

  • Tumor is HER2 negative by standard local testing methodology

  • Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 - 2

  • Measurable disease by response evaluation criteria in solid tumors (RECIST) v1.1

  • No prior systemic therapy for the present cancer given in the metastatic setting and > 6 months from administration of peri-operative chemotherapy, if applicable

    o Note: up to two prior cycles of mFOLFOX6 for the present illness is permitted if patients otherwise qualify for the study with adequate baseline imaging

  • At least 18 years of age

  • Adequate bone marrow and organ functions as defined by:

  • Absolute neutrophil count ≥ 1500 cells/ μL

  • Hemoglobin ≥ 8 g/ dL

  • Platelets > 100,000 / μL

  • Creatinine ≤ 1.5 x upper limit of normal (ULN) OR creatinine clearance ≥ 30 mL/min by Cockroft-Gault

  • Total bilirubin ≤ ULN

  • Aspartate aminotransferase (AST)/ Alanine aminotransferase (ALT) < 2.5 x ULN, unless with liver metastases and then must be <5 x ULN of normal

  • Women and men of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect pregnancy on study, she must notify her treating physician immediately.

  • Ability to understand the nature of this study protocol and give written informed consent.

  • Willingness and ability to comply with scheduled visits, treatment plans laboratory tests and other study procedures.

Exclusion Criteria:

  • Receipt of any investigational agents at the time of registration
  • Known, untreated brain metastases
  • Grade two or greater peripheral neuropathy
  • Presence of any additional active malignancy within the past three years where the malignancy is at least reasonably likely to later the course of therapy, require systemic therapy or interfere with imaging assessments
  • For those patients who are going to receive nivolumab
  • No active use of systemic corticosteroids at the time of enrollment, at a dose equivalent of 10 mg/day or prednisone
  • Clinically significant autoimmune disease which is active or has required systemic immunosuppression within the last two years
  • Prior organ transplant or bone marrow transplant
  • History of interstitial lung disease or pneumonitis
  • Uncontrolled intercurrent illness, including significant active infection, symptomatic congestive heart failure, unstable angina or active arrhythmia
  • Major surgery within the four weeks prior to initiation of study treatment
  • A history of allergy or hypersensitivity to any of the study drugs
  • Any additional significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from fully participating in the study

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Annen: 4week alternating FOLFOX and a combination chemotherapy regime FOLFIRI (sFOLFOXIRI),

A cycle will constitute 28 days of treatment, which will consist of one chemotherapy combination, either FOLFOX or FOLFIRI as below:

  1. Odd Cycles (e.g. 1, 3, 5, etc…) - mFOLFOX6 initiated on days 1 & 15: (Oxaliplatin 85 mg/m2 IV, leucovorin 400 mg/m2, 5FU 400 mg/m2 bolus, then 5FU 2400 mg/m2 over 46 hours)
  2. Even Cycles (e.g. 2,4,6, etc…) - FOLFIRI initiated on days 1 & 15: (Irinotecan 180 mg/m2 IV, leucovorin 400 mg/m2, 5FU 400 mg/m2 bolus, then 5FU 2400 mg/m2 over 46 hours)
  3. Nivolumab (optional, in-line with labelled approval) - 240 mg every 2 weeks

This is a Single Arm Phase II trial of q4week alternating FOLFOX and FOLFIRI (sFOLFOXIRI), with or without nivolumab, in advanced human epidermal growth factor receptor 2 (HER2) negative gastric and esophageal cancers (GEC).

The study treatment is a chemotherapy combination of either FOLFOX or FOLFIRI as below:

  1. mFOLFOX6: (Oxaliplatin 85 mg/m2 IV, leucovorin 400 mg/m2, 5-FU 400 mg/m2 bolus, then 5-FU 2400 mg/m2:
  2. FOLFIRI: (Irinotecan 180 mg/m2 IV, leucovorin 400 mg/m2, 5-FU 400 mg/m2 bolus, then 5-FU 2400 mg/m2
  3. Nivolumab(Optional) The chemotherapy combination of FOLFOX and FOLFIRI is a FDA approved treatment for advanced bowel and gastric

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Uønskede hendelser
Tidsramme: Tre år
Tre år
Objective Response Rate (ORR) as measured by Response Evaluation Criteria in Solid Tumors ( RECIST) criteria version 1.1
Tidsramme: Three Years

To determine the clinical efficacy of treatment regimen in terms of objective response rate.

Three Years
Progression Free Survival (PFS)
Tidsramme: Three Years

To determine the clinical efficacy of the study treatment in terms of progressive free survival.

Three Years
Overall Survival (OS)
Tidsramme: Three Years

To determine the clinical efficacy of the study treatment in terms of overall survival.

Three Years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Hovedetterforsker: Patrick Boland, MD, Rutgers Cancer Institute of New Jersey

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

13. juli 2022

Primær fullføring (Antatt)

1. februar 2027

Studiet fullført (Antatt)

1. august 2027

Datoer for studieregistrering

Først innsendt

29. mars 2022

Først innsendt som oppfylte QC-kriteriene

15. april 2022

Først lagt ut (Faktiske)

18. april 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

23. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

21. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • 072204
  • Pro2022000268 (Annen identifikator: Rutgers Cancer Institute of New Jersey)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

produkt produsert i og eksportert fra USA

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .